Dr. Jonathan Whitfield and Dr. Mariano Zacarías-Fluck, researchers in the Models of Cancer Therapies Group at VHIO, together with Dr….
Laura Soucek
Laura Soucek, an ICREA Research Professor, Director of VHIO’s Experimental Therapeutics Program, and Head of our Models of Cancer Therapies…
Peptomyc, the VHIO and ICREA spin-off co-founded and directed by Dr. Laura Soucek, ICREA professor and director of the VHIO…
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…
The biotech company Peptomyc SL announced today that it has been awarded €5 million blended financing from the Horizon Europe,…
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
Published in the journal Genes & Development*, results of a study led by Laura Soucek, co-Director of the Vall d’Hebron…
Results of VHIO-led pharmacokinetic analysis of Omomyc, a therapeutic mini-protein that targets the MYC oncogene which is found deregulated in…
Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few…
